PT  - JOURNAL ARTICLE
AU  - Aguirre, Rebecca Schneider
AU  - Hannon, Tamara S
AU  - Considine, Robert V
AU  - Patel, Yash
AU  - Kirkman, M Sue
AU  - Mather, Kieren J
TI  - Predictors of glycemic worsening in the next year in adults with screen-detected type 2 diabetes
AID  - 10.1101/2024.04.25.24306391
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.04.25.24306391
4099  - http://medrxiv.org/content/early/2024/04/27/2024.04.25.24306391.short
4100  - http://medrxiv.org/content/early/2024/04/27/2024.04.25.24306391.full
AB  - Background and Aims Identifying simple markers of risk for worsening glucose can allow care providers to target therapeutic interventions according to risk of worsening glycemic control. We aimed to determine which routine clinical measures herald near-term glycemic worsening in early type 2 diabetes(T2D).Methods The Early Diabetes Intervention Program (EDIP) was a clinical trial in individuals with screen-detected T2D [HbA1C 6.3+0.63%(45+5mmol/mol)]. During the trial some participants experienced worsening fasting blood glucose (FBG). We investigated the time course of FBG, HbA1c, weight, and other clinical factors to determine which might herald glycemic worsening over the next year.Results Progressors (62/219, 28.5%) had higher FBG than non-progressors at baseline [118 vs 130mg/dL (6.6 vs 7.2 mmol/L), p=<0.001]. FBG was stable except in the year of progression, when progressors exhibited a large 1-year rise [mean change 14.2mg/dL(0.79 mmol/L)]. Current FBG and antecedent year change in FBG were associated with progression(p<0.01), although the magnitude of change was too small to be of clinical utility (0.19 mg/dL; 0.01 mmol/L). Current or antecedent year change in HbA1c, weight, TG or HDL were not associated with progression. In the year of glycemic worsening, rising glucose was strongly associated with a concurrent increase in weight (p<0.001).Conclusions Elevated FBG but not HbA1c identified individuals at risk for imminent glycemic worsening; the subsequent large rise in glucose was associated with a short-term increase in weight. Glucose and weight surveillance provide actionable information for those caring for patients with early diabetes.HighlightsRecent change in fasting blood sugar is associated with near-term worsening of glycemiaChanges in weight, insulin, HbA1C were not informative for anticipating near-term worsening of glycemiaIncreasing glucose was strongly associated with concurrent weight gainCompeting Interest StatementThe authors have declared no competing interest.Funding StatementR.S.A. was supported by the National Institutes of Health (grant number 5T32-DK-065549-15). The original EDIP study was supported by an investigator-initiated grant from Bayer with additional support from the National Institutes of Health (grants P60 DK20542, P60 DK20579, GCRC M01RR00750, and M01RR00036).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Indiana University School of Medicine and Washington University School of Medicine approved the original EDIP study. The current manuscript used de-identified data.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authorsBMIbody mass index;EDIPEarly Diabetes Intervention Program;FBGfasting blood glucose;HOMA-IRHomeostasis Model Assessment of Insulin Resistance;IFGimpaired fasting glucose;IGTimpaired glucose tolerance;IGIinsulinogenic index;oDIoral disposition index;OGTToral glucose tolerance test;T2Dtype 2 diabetes